Biggest News Aggregation in the World
📰 Nasdaq Edit News

Page 6 - Nasdaq Edit News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Nasdaq Edit. Real-time updates on events, politics, business and more.

Pictet Asset Management SA Raises Position in Editas Medicine, Inc. (NASDAQ:EDIT)

Pictet Asset Management SA lifted its stake in Editas Medicine, Inc. (NASDAQ:EDIT – Get Rating) by 37.6% in the third quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 182,186 shares of the company’s stock after purchasing an additional 49,782 shares during the quarter. Pictet Asset Management […]
Michelle Robertson Marks Shearman Feng Zhang Jennifera Doudna Morgan Stanley Securities Exchange Commission

Pictet Asset Management SA Has $2.23 Million Holdings in Editas Medicine, Inc. (NASDAQ:EDIT)

Pictet Asset Management SA raised its stake in shares of Editas Medicine, Inc. (NASDAQ:EDIT – Get Rating) by 37.6% in the third quarter, according to its most recent 13F filing with the SEC. The fund owned 182,186 shares of the company’s stock after purchasing an additional 49,782 shares during the period. Pictet Asset Management SA […]
United Kingdom United States Michelle Robertson Marks Shearman Feng Zhang Jennifera Doudna

Editas Medicine (NASDAQ:EDIT) Price Target Cut to $43.00

Editas Medicine (NASDAQ:EDIT – Get Rating) had its price target reduced by investment analysts at Chardan Capital from $60.00 to $43.00 in a report issued on Wednesday, The Fly reports. The brokerage presently has a “buy” rating on the stock. Chardan Capital’s price objective would suggest a potential upside of 268.47% from the stock’s previous […]
United States Russell Investments Group Ltd Editas Medicine Inc Covestor Ltd Clarity Wealth Management Inc Great West Life Assurance Co

Stay Updated with Latest News

Get breaking news updates delivered to your inbox

Browse All News →

Editas Medicine (NASDAQ:EDIT) Hits New 12-Month Low at $9.68

Editas Medicine, Inc. (NASDAQ:EDIT – Get Rating) shares hit a new 52-week low during trading on Tuesday . The company traded as low as $9.68 and last traded at $9.68, with a volume of 1376 shares trading hands. The stock had previously closed at $10.00. A number of research analysts recently commented on EDIT shares. […]
Morgan Stanley Ahrens Investment Partners Editas Medicine Company Profile Covestor Ltd Editas Medicine Inc Goldman Sachs Group

Editas Medicine, Inc. (NASDAQ:EDIT) Expected to Announce Quarterly Sales of $5.32 Million

Equities analysts predict that Editas Medicine, Inc. (NASDAQ:EDIT – Get Rating) will post sales of $5.32 million for the current quarter, Zacks Investment Research reports. Five analysts have issued estimates for Editas Medicine’s earnings, with the lowest sales estimate coming in at $2.20 million and the highest estimate coming in at $10.00 million. Editas Medicine […]
Morgan Stanley Zacks Investment Research Goldman Sachs Group Editas Medicine Inc Guggenheim Capital Royal Bank

Bruce Eaton Sells 1,123 Shares of Editas Medicine, Inc. (NASDAQ:EDIT) Stock

Editas Medicine, Inc. (NASDAQ:EDIT – Get Rating) EVP Bruce Eaton sold 1,123 shares of the firm’s stock in a transaction on Friday, June 3rd. The stock was sold at an average price of $11.54, for a total transaction of $12,959.42. Following the completion of the sale, the executive vice president now owns 65,421 shares of […]
Dekabank Deutsche Girozentrale Bruce Eaton Morgan Stanley Mcguire Investment Group Capital Partners Patriot Financial Group Insurance Agency

Editas Medicine, Inc. (NASDAQ:EDIT) CFO Michelle Robertson Sells 1,527 Shares

Editas Medicine, Inc. (NASDAQ:EDIT – Get Rating) CFO Michelle Robertson sold 1,527 shares of Editas Medicine stock in a transaction that occurred on Friday, June 3rd. The stock was sold at an average price of $11.54, for a total value of $17,621.58. Following the completion of the sale, the chief financial officer now owns 82,667 […]
Michelle Robertson Robertw Baird Morgan Stanley Norges Bank Blackrock Inc Renaissance Technologies

Editas Medicine, Inc. (NASDAQ:EDIT) Given Average Recommendation of "Hold" by Brokerages

Editas Medicine, Inc. (NASDAQ:EDIT – Get Rating) has been assigned an average recommendation of “Hold” from the eleven analysts that are covering the company, MarketBeat reports. Two equities research analysts have rated the stock with a sell rating, three have issued a hold rating and three have assigned a buy rating to the company. The […]
United States Robertw Baird Morgan Stanley Russell Investments Group Ltd Principal Financial Group Inc Alphacrest Capital Management

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science